Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13838853 | 0.98 | OPRL1 (0.52) | OPRL1OPRM1MAOAMAOBKDM1A | |
| Ammonia Solution, Strong SCHEMBL28005559 | 0.90 | SLC6A3 (0.54) | OPRL1OPRM1MAOAMAOBKDM1A | |
| SCHEMBL24394081 | 0.89 | SLC6A3 (0.49) | OPRL1OPRM1MAOAMAOBKDM1A | |
| SCHEMBL9751737 | 0.88 | SLC6A3 (0.56) | OPRL1OPRM1MAOAMAOBKDM1A | |
| SCHEMBL27100094 | 0.84 | OPRM1 (0.45) | OPRL1OPRM1MAOAMAOBKDM1A | |
| SCHEMBL13197431 | 0.83 | SLC6A3 (0.51) | OPRL1OPRM1MAOAMAOBKDM1A | |
| Water SCHEMBL6827490 | 0.83 | OPRM1 (0.44) | OPRL1OPRM1MAOAMAOBKDM1A | |
| SCHEMBL25136611 | 0.79 | MAOA (0.44) | OPRL1OPRM1MAOAMAOBKDM1A | |
| SCHEMBL34470881 | 0.78 | PDE2A (0.42) | OPRL1OPRM1MAOAMAOBKDM1A | |
| SCHEMBL13073619 | 0.74 | OPRM1 (0.31) | OPRL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| EP-2627648-A1 | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | OPRL1 2665/4885OPRM1 3088/4885MAOA 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.